Intranasal administration of apelin-13 ameliorates cognitive deficit in streptozotocin-induced alzheimer’s disease model via enhancement of nrf2-ho1 pathways

HIGHLIGHTS

• What: The authors aimed to investigate Apelin-13`s mechanism of action in an in vivo model of AD induced by streptozocin (STZ). By analyzing parameters such as cognitive function, synaptic plasticity, oxidative stress markers, and signaling pathways, the authors aimed to clarify the therapeutic potential of Apelin-13 and its mechanism of action. After confirming the validity of the behavioral results, the authors focused on specific brain regions. The authors focused on changes that occurred in the hippocampus.
• Who: Hai Lu and collaborators from the State Key Laboratory of Medical Neurobiology, Institutes of Brain . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.